- Conditions
- Stargardt Disease
- Interventions
- OCU410ST
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 913
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age-Related Macular Degeneration
- Interventions
- MC-1101, Vehicle
- Drug
- Lead sponsor
- MacuCLEAR, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
- Interventions
- LFG316, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more
- Conditions
- Anesthesia, Local, Intravitreal Injection, Macular Edema, Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- Recens Cooling Anesthesia Device
- Device
- Lead sponsor
- Recens Medical, Inc.
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Reno, Nevada • Houston, Texas
- Conditions
- Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 50 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
- Genetic
- Lead sponsor
- Olix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Santa Maria, California • Oak Forest, Illinois • St Louis, Missouri + 2 more
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration
- Interventions
- avacincaptad pegol
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 53
- States / cities
- Campbell, California • Fresno, California • Fullerton, California + 49 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Samsung Bioepis Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 19
- States / cities
- Poway, California • Colorado Springs, Colorado • Fort Myers, Florida + 16 more
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
- Conditions
- Uveitic Macular Edema, Intraocular Inflammation
- Interventions
- Infliximab (intravitreal, 2.0mg/0.05ml)
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Uveitis, Macular Edema
- Interventions
- Efalizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- OPT-302, ranibizumab, sham intravitreal injection
- Biological · Other
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 49 more
- Conditions
- Geographic Atrophy
- Interventions
- Sham, Lampalizumab
- Other · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 36
- States / cities
- Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 55 Years to 120 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- All participants
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 18,457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Age Related Macular Degeneration
- Interventions
- Subretinally injected RetinoStat
- Drug
- Lead sponsor
- Oxford BioMedica
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
- Conditions
- Age-related Macular Degeneration
- Interventions
- Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
- Interventions
- Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
- Drug · Other · Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Macular Degenerative Disease
- Interventions
- Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation
- Other
- Lead sponsor
- Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Macular Degeneration
- Interventions
- Abicipar Pegol, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 71
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Encino, California + 61 more
- Conditions
- Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS, Cancer, Alzheimer Disease, Huntington Disease
- Interventions
- Biological sample collection
- Other
- Lead sponsor
- New York Stem Cell Foundation Research Institute
- Other
- Eligibility
- 1 Month to 100 Years
- Enrollment
- 1,279 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- KSI-301
- Drug
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
- Conditions
- Geographic Atrophy
- Interventions
- Sirolimus, Lidocaine
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 55 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 13
- States / cities
- Loma Linda, California • Sacramento, California • Jacksonville, Florida + 10 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,011 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 57
- States / cities
- Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more